| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：300482 | | 证券简称：万孚生物 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：123064 | | 债券简称：万孚转债 | | | | | | | | 转股价格：人民币 | | 27.00 元/股 | | | | | | | | 转股时间：2021 | 年 3 | 月 8 | 日至 | 2026 | 年 | 8 月 | 31 | 日 | 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所可转换公司 债券业务实施细则》的有关规定，广州万孚生物技术股份有限公司（以下简称"公 司"）现将 2025 年第三季度可转换公司债券（以下简称"可转债"）转股及公司股 份变动的情况公告如下： 一、 ...

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 29 yuan [2][8]. Core Views - The company's performance is under pressure in the short term, with a significant decline in revenue and profit. The total revenue for the first half of 2025 was 1.246 billion yuan, down 20.92%, and the net profit attributable to shareholders was 189 million yuan, down 46.82% [2][3]. - The company is making steady progress in expanding its overseas business, which is expected to help mitigate domestic market challenges [2][8]. Financial Summary - **Revenue and Profit Forecasts**: The projected total revenue for 2025 is 2.634 billion yuan, reflecting a year-on-year decrease of 14.1%. The net profit attributable to shareholders is expected to be 418 million yuan, down 25.5% [4][9]. - **Earnings Per Share (EPS)**: The EPS for 2025 is forecasted at 0.89 yuan, with a price-to-earnings (P/E) ratio of 24 [4][9]. - **Market Capitalization**: The total market capitalization of the company is approximately 9.956 billion yuan [5]. Business Segment Performance - **Chronic Disease Management Testing**: Revenue for this segment was 563 million yuan, down 26.06%. The company is responding to domestic market pressures by launching new products and enhancing its service model [8]. - **Infectious Disease Testing**: Revenue decreased to 379 million yuan, down 21.14%. The company is focusing on maintaining its market position while expanding its product offerings in overseas markets [8]. - **Drug Abuse Testing**: This segment showed a stable growth with revenue of 145 million yuan, up 4.26%, driven by e-commerce strategies [8]. - **Prenatal and Genetic Testing**: Revenue was 138 million yuan, down 11.67%, as the company focuses on product innovation to adapt to market changes [8]. Investment Recommendations - The report suggests that considering the domestic demand for products, the pace of international expansion, and stock compensation expenses, the net profit attributable to shareholders is expected to be 4.2 billion yuan, 4.9 billion yuan, and 5.9 billion yuan for 2025, 2026, and 2027 respectively [8].

Core Viewpoint - Wanfu Biology announced a stock repurchase plan, indicating confidence in its own stock value and commitment to shareholder returns [1] Summary by Category Company Actions - The company will implement a stock repurchase through a special account starting from September 26, 2025 [1] - A total of 13,000 shares will be repurchased, which represents 0.0028% of the company's total share capital [1]

Core Viewpoint - Wanfu Biological (300482.SZ) has initiated a share buyback program, purchasing a total of 13,000 shares, which represents 0.0028% of the company's total equity, at a total cost of 275,729.00 yuan [1] Summary by Category - **Share Buyback Details** - The buyback was conducted on September 26, 2025, through a centralized bidding transaction [1] - The highest and lowest transaction price for the shares was 21.21 yuan per share [1] - **Compliance and Regulations** - The buyback aligns with the company's share repurchase plan and complies with relevant laws and regulations [1]

Group 1 - Company Wanfu Bio announced a stock buyback on September 29, 2025, repurchasing approximately 13,000 shares, which represents 0.0028% of its total share capital, with a total transaction amount of about 280,000 yuan [1] - The maximum and minimum transaction price for the repurchased shares was 21.21 yuan per share [1] - For the year 2024, Wanfu Bio's revenue composition indicates that diagnostic products account for 97.59% of total revenue, while other products account for 2.41% [1] Group 2 - Wanfu Bio's market capitalization is currently 10 billion yuan [2] - The competition in the beverage industry is intensifying, with Farmer's Green Bottle launch leading to a significant market share decline of nearly 5 percentage points for Yibao [2]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-056 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 公司于 2025 年 9 月 26 日首次通过股票回购专用账户以集中竞价交易方式实 施回购，回购公司股份数量为 13,000 股，占公司总股本的 0.0028%，本次回购 股份的最高成交价为 21.21 元/股，最低成交价为 21.21 元/股，成交总金额为 275,729.00 元（不含交易费用）。本次回购符合公司回购股份方案及相关法律法 规的要求。 二、其他说明 公司首次回购股份的时间、回购股份数量及集中竞价交易的委托时段等均符 合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— —回购股份》的相关规定，具体如下： 1、公司未在下列期间内回购公司股票： （一）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中 ...

注：以上股东的持股数量为合并普通账户和融资融券信用账户后总的持股数量。 二、公司前十名无限售条件股东持股情况 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开第五届董事会第十四次会议，会议审议通过了《关于回购公司股份方案的议 案》。公司拟使用自有资金以集中竞价交易方式回购公司发行的人民币普通股股 份，用于实施后续员工持股计划或股权激励，具体内容可详见公司于 2025 年 9 月 23 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案暨 回购报告书的公告》（公告编号：2025-054）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回 ...

Core Viewpoint - Wanfu Bio plans to repurchase shares to boost investor confidence, with a total repurchase amount between 30 million and 60 million yuan, aiming to enhance long-term incentive mechanisms and promote business growth [2][3]. Group 1: Share Repurchase Announcement - The company announced a share repurchase plan using its own funds, with a total amount not less than 30 million yuan and not exceeding 60 million yuan, at a maximum price of 34.66 yuan per share [2]. - The estimated number of shares to be repurchased ranges from approximately 865,600 to 1,731,100, accounting for about 0.18% to 0.37% of the total share capital [2]. - The repurchase period is set for six months from the date of the board's approval of the final repurchase plan [2]. Group 2: Financial Performance - In the first half of 2025, the company faced significant challenges in the in vitro diagnostic industry, with revenue of 1.246 billion yuan, a year-on-year decrease of 20.92%, and a net profit of 189 million yuan, down 46.82% year-on-year [3]. - The company has increased its R&D investment as a core strategy to address industry pressures, with cumulative R&D expenditures reaching 1.513 billion yuan from 2022 to the first half of 2025 [3][4]. - R&D investment as a percentage of total revenue has shown an upward trend, with ratios of 7.87%, 15.26%, 14.3%, and 16.53% for the respective periods [3]. Group 3: Technological Advancements - The company achieved breakthroughs in several strategic areas, particularly in the chemiluminescence sector, launching the LA-6000 laboratory intelligent assembly line to expand terminal coverage [4]. - The company has optimized product performance for single-use chemiluminescence platforms, enhancing reagent sensitivity and stability to meet the demand for immediate and miniaturized testing solutions [4]. - As of June 30, 2025, the company holds 490 valid patents, including 141 invention patents, 264 utility model patents, and 85 design patents [4].

Core Viewpoint - Wanfu Bio plans to repurchase shares to boost investor confidence, with a total repurchase amount between 30 million and 60 million yuan, and a maximum price of 34.66 yuan per share [2] Group 1: Share Repurchase Details - The repurchase will involve approximately 865,600 to 1,731,100 shares, accounting for 0.18% to 0.37% of the company's total share capital [2] - The repurchase period is set for six months from the board's approval date [2] - The funding for the repurchase will come from the company's own funds, with the maximum repurchase amount representing 0.87% of total assets and 1.08% of net assets as of June 30, 2025 [2] Group 2: Company Background and Performance - Wanfu Bio, established in 1992 and listed in 2015, is a leading player in China's in vitro diagnostics sector, particularly in the POCT industry [3] - In the first half of 2025, the company faced significant challenges, with revenue dropping to 1.246 billion yuan, a year-on-year decrease of 20.92%, and net profit falling to 189 million yuan, down 46.82% [3] - The company has increased its R&D investment as a core strategy to address industry pressures, with total R&D spending from 2022 to the first half of 2025 amounting to 1.513 billion yuan [4] Group 3: R&D Achievements - Wanfu Bio has made significant advancements in strategic areas, particularly in the field of chemiluminescence, launching the LA-6000 laboratory intelligent assembly line [4] - The company has optimized product performance to meet the demand for instant and small-scale testing, gradually replacing traditional testing solutions [4] - As of June 30, 2025, Wanfu Bio holds 490 valid patents, including 141 invention patents, 264 utility model patents, and 85 design patents [4]

Core Viewpoint - Wanfu Biological (300482) has recently received four medical device registration certificates from the Guangdong Provincial Drug Administration, enhancing its product line in the in vitro diagnostic field [1] Product Approval Details - The four approved products include: - Fibrinogen (original) degradation product determination kit (immunoturbidimetric method) - Fibrinogen determination kit (coagulation method) - D-dimer determination kit (immunoturbidimetric method) - Anti-Xa determination kit (color substrate method) [1] - All four products have a registration certificate validity until 2030 and are used for assisting in the diagnosis of primary and secondary fibrinolysis, disseminated intravascular coagulation, and primary fibrinolytic syndrome, as well as monitoring thrombolytic efficacy and heparin activity [1] Market Demand and Competitive Position - Coagulation testing is a crucial component of clinical diagnosis, with increasing demand driven by an aging population and rising incidence of cardiovascular diseases [1] - The approval of these new products will complete the company's coagulation index detection solution, enhancing its core competitiveness in the in vitro diagnostic market [1]